NEWS

Press Releases

2025/03/12
Press Releases
GWOXI Stem Cell's new diabetes drug has been granted an invention patent.
文章引用自:Commercial Times
國璽幹細胞開發的糖尿病幹細胞新藥「怡導速」(GXIPC1®) 相繼取得美國、中國及台灣專利(示意圖)。

Developed by GWOXI Stem Cell, the new stem cell drug for diabetes, Yidaosu (GXIPC1®), has obtained patents in the United States, China, and Taiwan (illustration).

 GWOXI Stem Cell Secures Key Patents for Diabetes Treatment

Stem cell company GWOXI Stem Cell has successively obtained patents for its "Composition for Cell Differentiation Culture Medium, High-Insulin-Secreting Cells and Their Preparation Method" in the United States (Patent No. US12,195,754), China (Publication No. CN113736725), and Taiwan (Patent No. I776368). This strengthens the overall patent portfolio for the technological development of high-insulin-secreting cells and their preparation method, which will help accelerate the commercialization timeline.

The Rising Prevalence of Diabetes

One in every four adults is at risk of developing diabetes. To raise global awareness of diabetes prevention and control, the International Diabetes Federation has designated November 14 as World Diabetes Day. According to the National Health and Nutrition Examination Survey statistics from 2019-2023, as reported by the Health Promotion Administration, the prevalence of diabetes among Taiwanese adults aged 20 and over is 12.8%. The disease is also starting to show a younger-onset trend.

In its early stages, diabetes is often asymptomatic and thus neglected by most people. It's usually not until symptoms like increased eating, drinking, and urination, or weight loss appear, that people realize they have the disease. By then, they have often missed the opportunity for early intervention and treatment, and even the golden window to reverse the condition.

 

國璽專注於幹細胞新藥與技術研發,成功取得多項前瞻研發成果(示意圖)。

GWOXI, specializing in the R&D of new stem cell drugs and technologies, has successfully achieved multiple pioneering R&D results (illustration).

 

Based on their underlying mechanisms, the main types of diabetes are Type 1 diabetes, Type 2 diabetes, and gestational diabetes. If left untreated, high blood sugar can lead to complications such as cardiovascular disease, stroke, chronic kidney disease, foot ulcers, nerve damage, eye damage, and cognitive impairment. The impact of diabetes and its associated complications on public health is significant, creating an enormous medical burden.

The patent for "Composition for Cell Differentiation Culture Medium, High-Insulin-Secreting Cells and Their Preparation Method" uses a specific cell differentiation culture medium composition. This makes the high-insulin-secreting cells less susceptible to being consumed by macrophages when transplanted into the human body, allowing them to extend the duration of insulin secretion and have an excellent in vivo survival rate. This technology aims to treat endocrine diseases caused by the pancreas's inability to secrete sufficient insulin or the body's inability to use insulin effectively.

 

國璽將持續以台灣為研發基地,透過專利布局創造更多利基市場(示意圖)。
GWOXI will continue to use Taiwan as its R&D base to create more niche markets through its patent strategy (illustration).

 

GWOXI is a new stem cell drug development company with excellent innovative R&D capabilities, experienced R&D professionals, and a reliable stem cell technology platform and products. Its technology spans the upstream, midstream, and downstream of the regenerative medicine industry. Focused on innovation and R&D, and continuously investing research resources, the company has successfully achieved multiple pioneering R&D results. Valuing technology and talent, GWOXI will continue to use Taiwan as its R&D base to create more niche markets through its patent strategy, and collaborate with strategic alliance partners to advance together onto the world biomedical stage.